| Literature DB >> 32908211 |
John Chulhoon Park1, Sin-Hyeog Im2,3.
Abstract
Considerable evidence points to the critical role of the gut microbiota in physiology and disease. The administration of live microbes as a therapeutic modality is increasingly being considered. However, key questions such as how to identify candidate microorganisms and which preclinical models are relevant to recapitulate human microbiota remain largely unanswered. The establishment of a humanized gnotobiotic mouse model through the fecal microbiota transplantation of human feces into germ-free mice provides an innovative and powerful tool to mimic the human microbial system. However, numerous considerations are required in designing such a model, as various elements, ranging from the factors pertaining to human donors to the mouse genetic background, affect how microbes colonize the gut. Thus, it is critical to match the murine context to that of human donors to provide a continuous and faithful progression of human flora in mice. This is of even greater importance when the need for accuracy and reproducibility across global research groups are taken into account. Here, we review the key factors that affect the formulation of a humanized mouse model representative of the human gut flora and propose several approaches as to how researchers can effectively design such models for clinical relevance.Entities:
Mesh:
Year: 2020 PMID: 32908211 PMCID: PMC8080820 DOI: 10.1038/s12276-020-0473-2
Source DB: PubMed Journal: Exp Mol Med ISSN: 1226-3613 Impact factor: 8.718
Factors affecting the human gut microbiota.
| Factor | Impact on the gut microbiota | Ref. |
|---|---|---|
| USA, Malawi, Amazonas of Venezuela | Large variation in composition between western and non-western populations Malawian and Venezuelan children have higher flora diversity than American children Distinct flora characteristics between Malawian and Venezuelan children | [ |
| Italy, Burkina Faso | Bacteroidetes were enriched and Firmicutes were depleted in non-western children | [ |
| Italy, Tanzania | Higher flora diversity and richness among Tanzanians, with enriched | [ |
| Peru, USA | Higher flora diversity among Peruvians Proteobacteria, Spirochetes, and Actinobacteria, | [ |
| Bangladesh, USA | Bangladeshi children have higher flora diversity; | [ |
| Korea, Japan, China, USA | USA: highest Firmicutes Japan: highest Actinobacteria China: highest Bacteroidetes, Korea: highest | [ |
| America (African American, Asian and Pacific Islander, Caucasian, Hispanic) | 12 microbial taxa differ in abundance: | [ |
| Netherlands (Moroccan, Turk, Ghanaian, Dutch) | [ | |
Microbiota composition “matures” as children develop, normally after 3 years of age Bacterial diversity increases with age during childhood Undernourished children have “immature” gut flora compared with the progression of composition evolution of healthy children | [ | |
| Undernutrition | “Immature” microbial floras in undernourished children Altered metabolic pathways Up to 220 taxa differ in abundance | [ |
| Subsistence mode | The presence of the parasite Hunter-gatherers have higher Proteobacteria and Fishing populations have higher | [ |
| High-fat | Increase in F/B ratio, | [ |
| High-fiber | Decrease in F/B ratio Enrichment in Decrease in | [ |
| Enlargement of cecum, increase in n-butylate concentration, decrease in intestinal inflammation | [ | |
| Increase in Bacteroidetes ( | [ | |
| Enrichment in Firmicutes ( | [ | |
Factors affecting microbiota colonization in humanized murine gut flora models.
| Factors | Impact on the gut microbiota | Ref. |
|---|---|---|
| C57BL/6 | Higher Bacteroidetes, More susceptible to microbiota disruptions | [ |
| BALB/c | Higher diversity, higher F/B ratio, higher IgA levels | [ |
| Immunodeficient | Lower diversity, higher SCFA production, better FMT colonization | [ |
| 83% and 73% of taxa at the class and genus levels are transmitted to FMT recipient offspring | [ | |
| Gut microbiota resemblance between parents and offspring can last up to 21 weeks | [ | |
| Mouse genetic background can alter microbiota transmission | [ | |
| Fresh | Fresh sample usage may result in a flora composition most representative of the donor | [ |
| Storage at 37 °C for >24 h leads to alterations in the composition of the sample | [ | |
| Frozen | In mice, frozen sample transplants initially lead to low diversity after colonization but eventually stabilize after 7 days | [ |
| Cryopreservation may significantly lower the amount of viable bacteria | [ | |
| Freezing may alter the F/B ratio | [ | |
| If freezing is necessary, it should be done at −80 °C with maltodextrin-trehalose solution and thawed quickly at 37 °C | [ | |
| Rectal administration correlates with better transplant outcomes in clinical settings | [ | |
Rectal delivery can reduce sepsis occurrences Oral gavage may be easier and more convenient | [ | |
Comparison of clinical FMT study methods and outcomes.
| Study | Sample state | Sample preparation | Delivery method | Study size | |
|---|---|---|---|---|---|
| Van Nood et al., 2013[ | Fresh | Dilution with 0.9% NaCl Supernatant strained Used within 6 h of donation | Nasoduodenal tube | 16 | 81% |
| Youngster et al., 2014[ | Frozen at −80 °C | Under aerobic conditions Dilution in NaCl through a blender Sieving and centrifugation before resuspension in NaCl with 10% glycerol 1.6 g aliquoted into size 0 capsules and then into size 00 capsules before freezing at −80 °C Thawed at −20 °C before consumption within 2 h | Capsule consumption | 20 | 70% |
| Lee et al., 2014[ | Fresh | Fresh samples homogenized in 300 ml of water with a disposable spatula before 100 ml was transplanted | Retention enema | 94 | 47.9% |
| Lee et al., 2016[ | Fresh vs Frozen at −20 °C | Fresh samples diluted in fresh water and emulsified with a wooden spatula Strained through gauze Fresh samples stored at 5 °C before direct usage within 24 h or freezing at −20 °C Frozen samples thawed at 25 °C overnight and used within 24 h | Enema administration | 232 | 52.8% for frozen, 50.5% for fresh |
| Satokari et al., 2014[ | Frozen at −80 °C | Fecal suspension in 0.9% NaCl 10% glycerol added 30 g of feces aliquoted and frozen at −80 °C Thawed at room temperature for 4–5 h or at 37 °C | Lower endoscopic delivery into cecum | 26 patients for fresh, 23 Patients for frozen | 96% for both fresh and frozen |
| Kassam et al., 2012[ | Fresh | 150 g of fresh sample emulsified in 300 ml of sterile water prior to immediate delivery | Rectal enema | 27 | 81% |
| Hamilton et al., 2012[ | Fresh and frozen at −80 °C | 50 g of fresh sample diluted in 250 ml of saline water and homogenized in a blender under anaerobic conditions Strained through laboratory sieves Centrifuged and resuspended in saline Used immediately as fresh transplant or frozen at –80 °C with 10% glycerol and thawed for 2–4 h in ice bath | Colonoscopy biopsy channel into terminal ileum and cecum | 12 patients for fresh, 21 patients for frozen | 92% for fresh, 90% for frozen |
| Jiang et al., 2017[ | Fresh, frozen, and lyophilized | 50 g of fresh samples processed within 4 h of collection in 0.85% NaCl and mixed in a Stomacher 80 Master (Seward Laboratory System Inc., Davie, FL, USA) before filtering through gauze Fresh samples used within 2 h of preparation Frozen samples stored at −80 °C Lyophilized samples frozen at −80 °C for 6 h before processing in a Freeze Dry System (Labconco, Kansas City, MO, USA) and stored at 4 °C | Colonoscopic delivery into proximal colon | 25 fresh sample recipients, 24 frozen sample recipients, 23 lyophilized sample recipients | 100% for fresh, 83% for frozen, 78% for lyophilized |
| Rohlke et al., 2010[ | Fresh | Fresh sample suspended in saline with manual shaking in a suction canister before filtering and delivery | Colonscopic delivery into the ileum | 19 | 95% |
| MacConnachie et al., 2009[ | Fresh | 30 g of fresh sample in 0.9% saline Homogenized in a blender and filtered before transplanting 30 ml | Nasogastric delivery | 15 | 73% |
Fig. 1Schematic diagram of creating a humanized gnotobiotic mouse model.
In creating a relevant, effective, and reproducible humanized gnotobiotic mouse model, several key factors must be taken into consideration, including form whom the donor fecal samples are collected from, how the samples are processed, and which mouse is selected as the recipient. Optimization for matching the mouse feed to the donor’s diet will also be necessary to ensure efficient continuation of the donor’s microbiota within the mouse setting.